Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths in the world. However, there are currently few clinical diagnosis and treatment options available, and there is an urgent need for novel effective approaches. More research is being undertaken on immune-associate...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2023-02, Vol.28 (5), p.2211
Main Authors: Liu, Qiaoyun, Huang, Wei, Liang, Wenjin, Ye, Qifa
Format: Article
Language:English
Subjects:
Adaptive immunity
Antigen (tumor-associated)
Antigen-presenting cells
Biocompatible Materials
Biomaterials
Biomedical materials
Cancer therapies
Carcinoma, Hepatocellular - pathology
Chemotherapy
Drug delivery systems
Drug resistance
Drug therapy
Drugs
Genotype & phenotype
HCC
Health aspects
Hepatocellular carcinoma
Hepatoma
Humans
Hypoxia
Immune response (cell-mediated)
Immunology
Immunosurveillance
Immunotherapy
Liver cancer
Liver Neoplasms - pathology
Lymphocytes
Lymphocytes T
Macrophages
Magnetic resonance imaging
Metastasis
Microenvironments
Nanoparticles
Nanotechnology
Phagocytes
Pharmaceutical research
Phenotypes
Radiation therapy
Review
ROS
TAMs
Tumor cells
Tumor Microenvironment
Tumor-Associated Macrophages
Tumors
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths in the world. However, there are currently few clinical diagnosis and treatment options available, and there is an urgent need for novel effective approaches. More research is being undertaken on immune-associated cells in the microenvironment because they play a critical role in the initiation and development of HCC. Macrophages are specialized phagocytes and antigen-presenting cells (APCs) that not only directly phagocytose and eliminate tumor cells, but also present tumor-specific antigens to T cells and initiate anticancer adaptive immunity. However, the more abundant M2-phenotype tumor-associated macrophages (TAMs) at tumor sites promote tumor evasion of immune surveillance, accelerate tumor progression, and suppress tumor-specific T-cell immune responses. Despite the great success in modulating macrophages, there are still many challenges and obstacles. Biomaterials not only target macrophages, but also modulate macrophages to enhance tumor treatment. This review systematically summarizes the regulation of tumor-associated macrophages by biomaterials, which has implications for the immunotherapy of HCC.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules28052211